[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572210":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":22,"locations":32,"responsibleParty":53,"collaborators":22,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":22,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":22,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":35,"whyStopped":22,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study arm","EXPERIMENTAL","Methylprednisolone combined with concurrent chemoradiotherapy",[13,14,15],"Radiation: Radiotherapy","Drug: Concurrent chemotherapy","Drug: Methylprednisolone",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","Radiotherapy","Hypofractionated radiotherapy",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"DRUG","Concurrent chemotherapy","weekly albumin-bound paclitaxel (50 mg\u002Fm²) and cisplatin (25 mg\u002Fm²)",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Methylprednisolone","Methylprednisolone 2mg\u002Fkg, qd, concurrent with radiotherapy",[9],[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Sun yat-sen University Cancer Center","RECRUITING","Guanzhou","Guangdong","510000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],113.37117,23.06828,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":51,"phoneExt":22,"email":52},"Bo Qiu","CONTACT","862087343031","qiubo@sysucc.org.cn",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Hui Liu","Professor","100572210","phase-2-glucocorticoids-combined-with-concurrent-chemoradiotherapy-for-unresectable-thymoma-100572210",false,"NCT06730308","Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","Inclusion Criteria:\n\n* Histologically confirmed type AB or B1-3 thymoma.\n* Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).\n* Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.\n* Between the ages of 18 and 70 years, regardless of sex.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* No prior chest radiation.\n* Adequate organ Functions.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Contraindications to Methylprednisolone.\n* History of or Concurrent Malignancy.\n* Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.\n* Pregnant or Lactating Women.\n* Bleeding Disorders.\n* Recent Participation in Other Clinical Trials.\n* Drug Abuse or Severe Alcoholism.\n* Uncontrolled Seizures or Mental Disorders.\n* Severe Allergies or Specific Sensitivities.","ALL","18 Years","75 Years",{"count":68,"type":69},45,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.",[75],"Thymoma",[75,77,29],"Concurrent chemoradiotherapy","2024-12-11",{"date":80,"type":81},"2024-12-12","ACTUAL",{"date":83,"type":81},"2024-11-20",{"date":85,"type":69},"2028-11-19",{"name":5,"class":6},1]